AstraZeneca's digital health strategy. Pear and Cognoa studies.

Issue 046.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 56 percent open rate. Here's what's happening this week:

Working toward the next long-form report, which will be focused on musculoskeletal (MSK) digital therapeutics companies. (Like many, I was surprised by Hinge Health's $90 million raise earlier this year.) Send tips, rumors, and requests my way if this one is of interest.
Livongo abandoned its trademark for "Cuff to Cloud", which was its brand for the voice-enabled health nudging feature it has developed with Amazon's developer tools. Despite the trademark sunsetting, Livongo tells me the voice-enabled feature is still very much a part of its hypertension program.
Health Advances' Partner Andrew Matzkin has a worthwhile column outlining the ways the COVID--19 pandemic is likely to shape the future of

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

AstraZeneca’s digital health strategy. Pear and Cognoa studies.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

AstraZeneca’s digital health strategy. Pear and Cognoa studies.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.